Inhibition of proliferation by heparin and expression of p53 in cultured human vascular smooth muscle cells

Abstract

Human vascular smooth muscle cells (HVSMC) culturedtated by a mutant conformation-specific anti-p53 antibody in any of the five strains. In one of the five positive from restenotic lesions are resistant to inhibition of proliferation by heparin. We examined if altered expression strains there was concomitant human cytomegaloviral infection. No significant difference was found between of p53 protein might be related to this phenomenon. HVSMC were cultured from saphenous vein and p53 efficacy of heparin in the p53-positive and -negative strains. Furthermore heparin had no detectable effect on protein levels examined using immunocytochemistry, and by immunoprecipitation with antibodies specific for p53 protein levels. Although aberrant levels of p53 are detectable in a minority of HVSMC strains, these data wild-type or mutant conformations followed by SDS PAGE and immunoblotting. Inhibition of proliferation by do not support a role for altered p53 expression in resistance to the growth inhibitory effects of heparin in heparin was measured in 14-day growth assays. Elevated levels of p53 were found in five out of 41 HVSMC these cells. strains. The accumulated p53 protein was not precipi-

Obesity and Antiphospholipid Syndrome: A Particular Challenge in Pregnancy

“…115 Heparin has a variety of actions including anticoagulant activity and inhibitory actions on vascular smooth muscle cell proliferation and migration, as well as anti-inflammatory effects. [116][117][118] It is also known that heparin acts as an endogenous antiatherosclerotic factor, [118][119][120] and chronic use of heparin shows a blood pressure-lowering effect in hypertensive patients and experimental animals. 121,122 In endothelial cells, ET-1 has been shown to be suppressed by heparin in cultured bovine endothelial cells.…”

Novel metallo‐β‐lactamases inhibitors restore the susceptibility of carbapenems to New Delhi metallo‐lactamase‐1 (NDM‐1)‐harbouring bacteria

“…Here we employed the repurposing approach and found four NDM‐1 inhibitors from the FDA‐approved drugs. Dexrazoxane is used mainly as an anti‐tumour adjuvant drug to alleviate the cardiotoxicity induced by anthracycline (Popelová et al, 2009); nordihydroguaiaretic acid is an antioxidant applied mostly in the food industry (Peralta et al, 2018); embelin, a natural compound isolated from Embeliaribes , is a well‐known antagonist for X‐linked inhibitor of apoptosis protein (XIAP) used for the treatment of various cancers (Sheng et al, 2020); candesartan cilexetil is a potent antagonist of angiotensin II (AT 1 ) receptor approved to treat hypertension in adults (Sawhney et al, 1997). These four inhibitors showed broad‐spectrum inhibitory effects on metallo‐β‐lactamases either by chelating zinc ions (dexrazoxane, embelin and candesartan cilexetil) or by directly engaging metallo‐β‐lactamases (nordihydroguaiaretic acid).…”

Novel MBLs inhibitors screened from FDA-approved drug library restore the susceptibility of carbapenems to NDM-1-harbouring bacteria

“…Here we employed the repurposing approach and found four NDM-1 inhibitors from the FDA-approved drugs. Dexrazoxane is used mainly as an anti-tumor adjuvant drug to alleviate the cardiotoxicity induced by anthracycline [36]; NDGA is an antioxidant applied mostly in the food industry [37]; embelin, a natural compound isolated from Embeliaribes, is a well-known antagonist for X-linked inhibitor of apoptosis protein (XIAP) used for the treatment of various cancers [38]; CAN is a potent blocker of angiotens in II receptor approved to treat hypertension in adults [39]. These four inhibitors showed broad-spectrum inhibitory effects on MBLs either by chelating zinc ions (dexrazoxane, embelin and CAN) or by directly engaging MBLs (NDGA).…”